Triumeq Tablet, Film Coated
Product Images NDC 49702-231
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Triumeq (NDC 49702-231). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Viiv Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Dolutegravir Chemical Structure (Triumeq Spl Graphic 02)
Epivir Chem Struc (Triumeq Spl Graphic 03)
Triumeq 30 Count Carton (Triumeq Spl Graphic 04)
Triumeq Spl Graphic 05
Triumeq Spl Graphic 06
Triumeq Spl Graphic 07
Triumeq Spl Graphic 08
Triumeq Spl Graphic 09
Each tablet of NDC 49702-231-13 contains abacavir, dolutegravir sodium, and lamivudine. Abacavir and dolutegravir treat HIV while lamivudine helps prevent hepatitis B. This medication comes in a child-resistant package and must be stored at controlled room temperature. The prescribing information provides dosage instructions, and a medication guide should be given to the patient along with a warning card.*
Triumeq Spl Graphic 10
Triumeq P is a medication for oral suspension containing abacavir, dolutegravir, and lamivudine. It is available in bottles containing 90 tablets of 60 mg/5 mg/30 mg strength accompanied by a dosing cup, prescribing information, and medication guide. Triumeq and Triumeq PD are not interchangeable. Authorized dispensers must give patients a Medication Guide and Warning Card from the carton each time TRIUMEQ PD is dispensed. Dosage information is available in the prescribing information.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.